Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Brunner AM, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, Garcia-Manero G, Vey N, Wermke M, Janssen JJWM, Narayan R, Fleming S, Loo S, Tovar N, Kontro M, Ottmann OG, Naidu P, Sun H, Han M, White R, Zhang N, Mohammed A, Sabatos-Peyton CA, Steensma DP, Rinne ML, Borate UM, Wei AH.
Brunner AM, et al. Among authors: narayan r.
Am J Hematol. 2024 Feb;99(2):E32-E36. doi: 10.1002/ajh.27161. Epub 2023 Nov 22.
Am J Hematol. 2024.
PMID: 37994196
Clinical Trial.